Innovent Reports the First Patient Dosing of Efdamrofusp Alfa (IBI302) in the P-III Clinical Study (STAR) for Neovascular Age-related Macular Degeneration
Shots:
- The first patient has been dosed in the P-III study (STAR) evaluating IBI302 (8mg) vs aflibercept (2mg) in a ratio (1:1) in 600 patients with nAMD. All patients will have visits q4w for the entire study duration
- The 1EPs of the study are changed from baseline in best corrected visual acuity (BCVA) letters in the study eye based on an avg. at 44, 48, and 52wk. while all patients will continue to receive IVT inj. up to 96wk. with a final study visit at 100wk.
- Efdamrofusp alfa (IBI302), a recombinant fully human anti-VEGF and anti-complement bispecific fusion protein. Additionally, the preliminary results from the P-I & II clinical studies showed a favorable safety and efficacy profile incl. improvements in visual acuity and reduction in retinal edema
Ref: PR Newswire | Image: Innovent
Related News:- Regeneron Reports Two-Year (PULSAR) Trial Results of Eylea HD (aflibercept) for Wet Age-Related Macular Degeneration
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
